Orexo AB Share Price OTC Markets

ORXOY

US68616W1027

Pharmaceuticals

Delayed OTC Markets 19:20:45 07/10/2026 BST			5-day change	1st Jan Change
0.7500 ^USD	+2.88%		0.00%	-71.15%

09:34am	15 stocks have so far today hit new 52-week lows on the Stockholm Stock Exchange	FW
10-15	14 stocks have so far today hit new 52-week lows on the Stockholm Stock Exchange	FW

Last Transcript: Orexo AB

Orexo AB, Q2 2026 Earnings Call, Jul 16, 2026

07-16

More transcripts

Analysts' recommendations: Orexo AB

08-31	Orexo nears DOJ settlement, DNB Carnegie sees positive outcome - commissioned analysis	FW
05-19	DNB Carnegie raises fair value for Orexo following positive preclinical data for OX390	FW
01-02	DNB Carnegie Raises Target Value for Orexo Following Zubsolv Deal	FW
16/10/25	DNB Carnegie Raises Target Value for Orexo in Commissioned Analysis	FW
05/09/25	Orexo's Preclinical Data on AmorphOX Formulations Deemed Promising by DNB Carnegie	FW

More recommendations

Managers and Directors: Orexo AB

Manager	Title	Age	Since
Nikolaj Sørensen CEO	Chief Executive Officer	54	04/02/2013
Fredrik Järrsten DFI	Director of Finance/CFO	59	31/08/2022
Jonas Savmarker CTO	Chief Tech/Sci/R&D Officer	-	30/09/2024

Director	Title	Age	Since
Staffan Lindstrand BRD	Director/Board Member	64	31/12/2001
George Wilkinson BRD	Director/Board Member	70	10/04/2019
Christine Rankin BRD	Director/Board Member	62	31/03/2022

More insiders

Specialty & Advanced Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OREXO AB	+2.88%	0.00%	-	-	21.49M
ELI LILLY AND COMPANY	+4.73%	+11.55%	+60.85%	+122.57%	1,106B
JOHNSON & JOHNSON	+2.38%	+4.22%	+33.75%	+69.35%	612B
ABBVIE INC.	+2.00%	+4.88%	+23.99%	+96.77%	500B
ROCHE HOLDING AG	+2.30%	+8.17%	+38.46%	+62.85%	367B
MERCK & CO., INC.	+3.21%	+4.28%	+71.52%	+44.20%	354B
NOVARTIS AG	+1.54%	+5.45%	+20.80%	+48.35%	286B
ASTRAZENECA PLC	+1.27%	+5.36%	-0.24%	+20.17%	256B
AMGEN INC.	+2.50%	+5.32%	+43.34%	+55.94%	230B
GILEAD SCIENCES, INC.	+1.41%	+4.93%	+26.07%	+99.50%	190B
Average	+2.34%	+5.27%	+35.39%	+68.86%	433.35B
Weighted average by Cap.	+2.81%	+6.49%	+41.07%	+80.96%

See all sector performances

Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.

Employees

Sector

Pharmaceuticals

Calendar

10-22 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
14/10/26	US$0.000000	-	8

Delayed Quote OTC Markets

More quotes

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Orexo AB

Company calendar

Market Cap	213M 21.49M 19.16M 17.75M 16.13M 30.28M 2.04B 30.77M 83.69M 1.06B 80.63M 78.94M 3.4B	P/E 2024	-2.97x	P/E 2025	1.63x
Enterprise Value	-208M -21.01M -18.73M -17.35M -15.77M -29.6M -1.99B -30.08M -81.82M -1.04B -78.82M -77.17M -3.33B	EV / Sales 2024	1.62x	EV / Sales 2025	23.8x
Free-Float	78.37%	Yield 2024 *	-	Yield 2025	-

09:34am	15 stocks have so far today hit new 52-week lows on the Stockholm Stock Exchange	FW
10-15	14 stocks have so far today hit new 52-week lows on the Stockholm Stock Exchange	FW
10-14	Orexo reports promising results for oral semaglutide tablet	FW
10-14	Orexo AB (Publ.) Reports Promising Initial Results from First Preclinical Pharmacokinetic in Vivo Study of Oral Semaglutide Tablet Based on Amorphox® Technology	CI
10-13	17 stocks have so far today hit new 52-week lows on the Stockholm Stock Exchange	FW
10-09	20 stocks have hit new 52-week lows on the Stockholm Stock Exchange so far today	FW
10-06	CEO interview with Nikolaj Sørensen at Orexo ahead of the upcoming offering	FW
10-06	Orexo Plans SEK250 Million Rights Issue to Fund Drug Development	MT
10-06	Stockholm exchange set to open higher	FW
10-06	Orexo seeks to raise SEK 250m in offering	FW
09-30	Orexo Submits Revised US FDA New Drug Application for Opioid Overdose Drug	MT
09-29	Orexo resubmits FDA application for Izipry	FW
09-29	Orexo Resubmits Application for Izipry to FDA	FW

10-14	Orexo : reports encouraging bioavailability in first in vivo study of oral semaglutide formulation based on AmorphOX	PU
10-06	Orexo: Withdrawing fair value range	AQ
10-06	Notice of Extraordinary General Meeting of Orexo	AQ
10-06	Orexo resolves on a rights issue of approximately 250 MSEK subject to approval by an extraordinary general meeting and provides a financial update	AQ
09-29	Orexo resubmits NDA for IZIPRY™ to the FDA, a high-dose rescue medication for opioid overdose	AQ

1 day	+2.88%
Current month	-31.82%
1 month	-46.04%
3 months	-58.33%
6 months	-71.70%
Current year	-71.15%

1 month	0.73	1.26
Current year	0.73	2.65
1 year	0.73	3
3 years	0.73	4.05
5 years	0.73	4.05
10 years	0.73	9

Orexo AB Share Price OTC Markets

Stocks

ORXOY

US68616W1027

Pharmaceuticals

Valuation: Orexo AB

Chart: Orexo AB

Latest news: Orexo AB

Last Transcript: Orexo AB

Analysts' recommendations: Orexo AB

Press Releases: Orexo AB

Quotes and Performance

Price Extremes

Managers and Directors: Orexo AB

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

	2024	2025
Net sales	590M 59.57M 53.1M 49.19M 44.73M 83.93M 5.65B 85.31M 232M 2.95B 224M 219M 9.44B	26M 2.63M 2.34M 2.17M 1.97M 3.7M 249M 3.76M 10.22M 130M 9.85M 9.64M 416M
Net income	-203M -20.5M -18.27M -16.92M -15.39M -28.88M -1.94B -29.35M -79.83M -1.02B -76.9M -75.29M -3.25B	639M 64.55M 57.54M 53.3M 48.46M 90.94M 6.12B 92.43M 251M 3.2B 242M 237M 10.22B
Net Debt	353M 35.61M 31.74M 29.41M 26.74M 50.17M 3.38B 51M 139M 1.76B 134M 131M 5.64B	-421M -42.5M -37.88M -35.09M -31.91M -59.87M -4.03B -60.86M -166M -2.11B -159M -156M -6.73B